Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jan 07, 2026

SELL
$28.04 - $37.2 $3,056 - $4,054
-109 Closed
0 $0
Q1 2025

Jan 07, 2026

BUY
$37.76 - $92.13 $4,115 - $10,042
109 New
109 $4.12 Million
Q4 2024

Jan 07, 2026

BUY
$80.97 - $117.93 $12,064 - $17,571
149 New
149 $12.2 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.87B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Aventura Private Wealth, LLC Portfolio

Follow Aventura Private Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aventura Private Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aventura Private Wealth, LLC with notifications on news.